STAT

Opinion: It’s time for Canada to embrace universal pharmacare and protect drug coverage from corporate erosion

Changing health care takes leadership and the ability to stand up to a private sector that knows how to exert pressure. But it has been successfully done before.

President Trump recently unveiled an executive order — originally titled “Protecting Medicare from Socialist Destruction” — that calls for expanding private coverage rather than moving toward single payer, publicly funded “Medicare for All.” In Canada, we are working on protecting Medicare — our country’s publicly funded health care system — from corporate encroachment.

The worst aspect of Canadian health care today is the part that is outside of our single-payer system: prescription medicines. Currently, the

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks